

## **Treatment of Alzheimer's disease**

Dr. Eti Yoles, Immunobrain Checkpoint Ltd. Israel

ImmunoBrain Checkpoint (IBC) is a biotechnology company developing the first immune modulation-based, disease-modifying therapy for Alzheimer's Disease (AD) and other neurodegenerative diseases. The Company's technology is derived from decades of scientific discoveries in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science, demonstrating the need to augment peripheral immune activity for brain repair by blocking inhibitory immune checkpoint pathways.

IBC's expertise is in the crosstalk between the Central Nervous System and the Immune System. Its IP, licensed from Yeda, covers the use of a wide range of immune checkpoint inhibitors for the treatment of neurodegenerative diseases. IBC is currently advancing its proprietary antibody to begin a first in human clinical trial for treatment of Alzheimer's Disease within 24 months. The Company is also developing antibodies directed at other immune checkpoints to treat additional neurodegenerative diseases.